权益分类	功能权益	普通用户	{{item.name}}会员
{{category.name}}	{{benefitItem.name}}

Th1/Th2 balances in patients with cancer

癌症患者的 Th1/Th2 平衡

基本信息

批准号：
11671281
负责人：
SHIBATA Masahiko
金额：
$ 2.11万
依托单位：
Nihon University School of Medicine
依托单位国家：
日本
项目类别：
Grant-in-Aid for Scientific Research (C)
财政年份：
1999
资助国家：
日本
起止时间：
1999 至 2000
项目状态：
已结题

来源：
https://kaken.nii.ac.jp/grant/KAKENHI-PROJECT-11671281/
关键词：
gastric cancer colorectal cancer cell-mediated immunity cachexia helper T cell Th1 Th2 balances サイトカイン Th_1 Th_2バランス免疫抑制

项目摘要

A suppression of cell-mediated immune reaction in the patients with malignant diseases is well known and the mechanisms of it has long been studied. IL-12 has been reported as one of the strongest immune modulators that induce a production of interferon-gamma (IFN-G), however, IL-10 which is one of the immune-suppressing Th2 cytokines was reported to increase in the patients treated with IL-12. In order to find how this phenomenon exist in patients with neoplastic diseases, 39 normal volunteer and 61 patients with gastric and colorectal cancer were entered in this study. The ptoduction of IL-12 by peripheral blood mononuclear cells with a stimulation of staphylococcus aureus, those of IFN-G and IL-10 with a stimulation of phytohemagglutinin were studied. The concentrations of each cytokine in culture supernatant was measured by enzyme immunoassay after 24 hours of stimulation. The production of IL-12 were decreased along with a advance of the diseases and it was correlated to a nutritional damage in the patients. Those of IFN-G in the patients was uniformly decreased than those in normal donor, and those of IL-10 was increased in the patients with cachexia. The production of IL-10 by PBMC with a stimulation of IL-12 was significantly higher in the patients than in normal donor and there was no difference in those of IFN-G.Thus it seems to be necessary to decrease Th2 response to obtain an effective Th1 response by immunotherapy using cytokines such as IL-12.

恶性肿瘤患者的细胞免疫反应受到抑制是众所周知的，其机制也一直被研究。据报道，IL-12是诱导产生干扰素-γ（IFN-G）的最强免疫调节剂之一，然而，据报道，IL-10是免疫抑制性Th 2细胞因子之一，在用IL-12治疗的患者中增加。为了探讨肿瘤性疾病患者中这种现象的存在，本研究选择了39例正常志愿者和61例胃癌、结直肠癌患者作为研究对象。研究了金黄色葡萄球菌刺激外周血单个核细胞产生IL-12、植物血凝素刺激外周血单个核细胞产生IFN-G和IL-10的情况。刺激24小时后，通过酶免疫测定法测量培养上清液中每种细胞因子的浓度。IL-12的产生沿着疾病的进展而减少，并与患者的营养损害有关。患者血清IFN-G水平较正常人一致下降，而IL-10水平在恶病质患者中升高。IL-12刺激PBMC产生IL-10显著高于正常人，而IFN-γ无显著差异。因此，用IL-12等细胞因子进行免疫治疗，降低Th 2应答，以获得有效的Th 1应答，似乎是必要的。